Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of Various Formulations of PWT-143 in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2017
At a glance
- Drugs ME 401 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; First in man
- Sponsors MEI Pharma
- 21 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
- 21 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.
- 09 Nov 2016 According to a MEI Pharma media release, data from this study will be presented at at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History